{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:21Z","timestamp":1784557041103,"version":"3.55.0"},"reference-count":23,"publisher":"Bioscientifica","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"<jats:p>\n                    The aim of this study was to assess the usefulness of neuron-specific enolase (NSE) concentrations as a prognostic factor in patients with neuroendocrine neoplasms and to determine the relationship between NSE and clinicopathological features. Serum NSE levels were measured in 179 NEN patients before treatment. It was found that NSE levels in patients with a primary pancreatic location were higher compared to patients with a small intestine lesion (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.015). NSE levels were significantly higher in patients with primary pancreatic location with histological grade G2 compared with the group with low-grade G1 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.047). Patients with initial liver involvement showed significantly higher NSE levels compared to patients with tumour location in the pancreas (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.009). Statistical analysis confirmed that higher NSE levels were associated with disease progression (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001) in both the overall study group and in patients with tumours in the pancreas and small intestine. During treatment monitoring, an increase in median NSE concentrations was observed in patients with persistent progression with subsequent blood draws, and a decrease in NSE concentrations was observed in patients with disease stabilisation. We showed that NSE concentrations have prognostic value for progression-free survival in addition to primary liver involvement. In conclusion, the most important results of the study include the demonstration of an association between NSE concentrations and clinical status, which confirms its usefulness in patient monitoring and as a potential predictive indicator for progression-free survival in patients with NENs.\n                  <\/jats:p>","DOI":"10.1530\/ec-21-0647","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T09:28:43Z","timestamp":1658914123000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":7,"title":["Serum levels of neuron-specific enolase as a prognostic factor for disease progression in patients with GET\/NEN in the pancreas and the small intestine"],"prefix":"10.1530","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-423X","authenticated-orcid":true,"given":"Malgorzata","family":"Fuksiewicz","sequence":"first","affiliation":[{"name":"Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kowalska","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Kolasinska-Cwikla","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Kotowicz","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Markers, Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Resuscitation","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.resuscitation.2019.07.003","article-title":"Neuron-specific enolase (NSE) improves clinical risk scores for prediction of neurological outcome and death in cardiac arrest patients: results from a prospective trial","volume":"142","author":"Luescher","year":"2019","unstructured":"Luescher TMueller JIsenschmid CKalt JRasiah RTondorf TGamp MBecker CSutter RTisljar KNeuron-specific enolase (NSE) improves clinical risk scores for prediction of neurological outcome and death in cardiac arrest patients: results from a prospective trial. Resuscitation201914250\u201360. (https:\/\/doi.org\/10.1016\/j.resuscitation.2019.07.003)10.1016\/j.resuscitation.2019.07.003"},{"key":"bib2","series-title":"Resuscitation","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.resuscitation.2019.04.021","article-title":"Usefulness of neuron specific enolase in prognostication after cardiac arrest: impact of age and time to ROSC","volume":"139","author":"Wihersaari","year":"2019","unstructured":"Wihersaari LTiainen MSkrifvars MBBendel SKaukonen KMVaahersalo JRomppanen JPettil\u00e4 VReinikainen M & FINNRESUSCIStudy Group. Usefulness of neuron specific enolase in prognostication after cardiac arrest: impact of age and time to ROSC. Resuscitation2019139214\u2013221. (https:\/\/doi.org\/10.1016\/j.resuscitation.2019.04.021)10.1016\/j.resuscitation.2019.04.021"},{"key":"bib3","series-title":"BJU International","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/bju.13493","article-title":"Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy","volume":"119","author":"Heck","year":"2017","unstructured":"Heck MMThaler MASchmid SCSeitz AKTauber RK\u00fcbler HMaurer TThalgott MHatzichristodoulou GH\u00f6ppner MChromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy. BJU International201711930\u201337. (https:\/\/doi.org\/10.1111\/bju.13493)10.1111\/bju.13493"},{"key":"bib4","series-title":"BJU International","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/bju.15086","article-title":"Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer","volume":"127","author":"Szarvas","year":"2021","unstructured":"Szarvas TCsizmarik AFazekas TH\u00fcttl ANyir\u00e1dy PHadaschik BGr\u00fcnwald VP\u00fcllen LJur\u00e1nyi ZKocsis ZComprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. BJU International202112744\u201355. (https:\/\/doi.org\/10.1111\/bju.15086)10.1111\/bju.15086"},{"key":"bib5","series-title":"EJNMMI Research","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13550-020-00640-2","article-title":"Neuron-specific enolase has potential value as a biomarker for [(18)F]FDG\/[(68)Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients","volume":"10","author":"Rosar","year":"2020","unstructured":"Rosar FRibbat KRies MLinxweiler JBartholom\u00e4 MMaus SSchreckenberger MEzziddin SKhreish F. Neuron-specific enolase has potential value as a biomarker for [(18)F]FDG\/[(68)Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. EJNMMI Research20201052. (https:\/\/doi.org\/10.1186\/s13550-020-00640-2)10.1186\/s13550-020-00640-2"},{"key":"bib6","series-title":"Anticancer Research","first-page":"5193","article-title":"The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy of EGFR-TKIs in patients with advanced-stage NSCLC","volume":"34","author":"Fiala","year":"2014","unstructured":"Fiala OPesek MFinek JBenesova LMinarik MBortlicek ZTopolcan O. The role of neuron-specific enolase (NSE) and thymidine kinase (TK) levels in prediction of efficacy of EGFR-TKIs in patients with advanced-stage NSCLC. Anticancer Research2014345193\u20135198."},{"key":"bib7","series-title":"Medical Science Monitor","doi-asserted-by":"publisher","first-page":"675","DOI":"10.12659\/MSM.913054","article-title":"Neuron-specific enolase is an independent prognostic factor in resected lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements","volume":"25","author":"Li","year":"2019","unstructured":"Li SCao LWang XWang FWang LJiang R. Neuron-specific enolase is an independent prognostic factor in resected lung adenocarcinoma patients with anaplastic lymphoma kinase gene rearrangements. Medical Science Monitor201925675\u2013690. (https:\/\/doi.org\/10.12659\/MSM.913054)10.12659\/MSM.913054"},{"key":"bib8","series-title":"British Journal of Cancer","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/bjc.1994.391","article-title":"Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC)","volume":"70","author":"J\u00f8rgensen","year":"1994","unstructured":"J\u00f8rgensen LGOsterlind KHansen HHCooper EH. Serum neuron-specific enolase (S-NSE) in progressive small-cell lung cancer (SCLC). British Journal of Cancer199470759\u2013761. (https:\/\/doi.org\/10.1038\/bjc.1994.391)10.1038\/bjc.1994.391"},{"key":"bib9","series-title":"British Journal of Cancer","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/bjc.1990.134","article-title":"Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance?","volume":"61","author":"Harding","year":"1990","unstructured":"Harding MMcAllister JHulks GVernon DMonie RPaul JKaye SB. Neurone specific enolase (NSE) in small cell lung cancer: a tumour marker of prognostic significance?British Journal of Cancer199061605\u2013607. (https:\/\/doi.org\/10.1038\/bjc.1990.134)10.1038\/bjc.1990.134"},{"key":"bib10","series-title":"Lancet","first-page":"583","article-title":"Serum neuron-specific enolase a marker for disease extent and response to therapy of small-cell lung cancer","volume":"1","author":"Carney","year":"1982","unstructured":"Carney DNMarangos PJIhde DCBunn PAJrCohen MHMinna JDGazdaret AF. Serum neuron-specific enolase a marker for disease extent and response to therapy of small-cell lung cancer. Lancet19821583\u2013585. (https:\/\/doi.org\/10.1016\/s0140-6736(8291748-2)"},{"key":"bib11","series-title":"Clinical and Translational Oncology","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12094-017-1617-2","article-title":"Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer","volume":"19","author":"Zhou","year":"2017","unstructured":"Zhou MWang ZYao YZhou HLiu MSun J. Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer. Clinical and Translational Oncology201719865\u2013873. (https:\/\/doi.org\/10.1007\/s12094-017-1617-2)10.1007\/s12094-017-1617-2"},{"key":"bib12","series-title":"Cancer Management and Research","first-page":"13607","article-title":"Progastrin-releasing peptide precursor and neuron-specific enolase predict the efficacy of first-line treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations","volume":"12","author":"Dong","year":"2020","unstructured":"Dong JTong SShi XWang CXiao XJi WSun Y. Progastrin-releasing peptide precursor and neuron-specific enolase predict the efficacy of first-line treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations. Cancer Management and Research20201213607\u201313616. (https:\/\/doi.org\/10.2147\/CMAR.S285121)"},{"key":"bib13","series-title":"Best Practice and Research: Clinical Gastroenterology","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.bpg.2012.12.006","article-title":"Biochemical markers for gastroenteropancreaticneuroendocrine tumours (GEP-NETs)","volume":"26","author":"Kanakis","year":"2012","unstructured":"Kanakis GKaltsas G. Biochemical markers for gastroenteropancreaticneuroendocrine tumours (GEP-NETs). Best Practice and Research: Clinical Gastroenterology201226791\u2013802. (https:\/\/doi.org\/10.1016\/j.bpg.2012.12.006)10.1016\/j.bpg.2012.12.006"},{"key":"bib14","series-title":"JAMA Oncology","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","unstructured":"Dasari AShen CHalperin DZhao BZhou SXu YShih TYao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncology201731335\u20131342. (https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589)10.1001\/jamaoncol.2017.0589"},{"key":"bib15","series-title":"Endocrine Connections","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1530\/EC-18-0059","article-title":"Prognostic value of chromogranin A in patients with GET\/NEN in the pancreas and the small intestine","volume":"7","author":"Fuksiewicz","year":"2018","unstructured":"Fuksiewicz MKowalska MKolasinska-Cwikla ACwikla JBSawicki \u0141Roszkowska-Purska KDrygiel JKotowicz B. Prognostic value of chromogranin A in patients with GET\/NEN in the pancreas and the small intestine. Endocrine Connections20187803\u2013810. (https:\/\/doi.org\/10.1530\/EC-18-0059)10.1530\/EC-18-0059"},{"key":"bib16","series-title":"Oncology Letters","first-page":"1497","article-title":"Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression","volume":"17","author":"Zhang","year":"2019","unstructured":"Zhang CHuang YLong JYao XWang JZang SQu WWang F. Serum chromogranin A for the diagnosis of gastroenteropancreatic neuroendocrine neoplasms and its association with tumour expression. Oncology Letters2019171497\u20131504. (https:\/\/doi.org\/10.3892\/ol.2018.9795)"},{"key":"bib17","series-title":"Journal of Clinical Endocrinology and Metabolism","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1210\/jc.2011-0666","article-title":"Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus","volume":"96","author":"Yao","year":"2011","unstructured":"Yao JCPavel MPhan ATKulke MHHoosen SSt Peter JCherfi A\u00d6berg KE. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. Journal of Clinical Endocrinology and Metabolism2011963741\u20133749. (https:\/\/doi.org\/10.1210\/jc.2011-0666)10.1210\/jc.2011-0666"},{"key":"bib18","series-title":"Annals","first-page":"844","article-title":"Gastroenteropancreatic","volume":"31","author":"Pavel","year":"2020","unstructured":"Pavel M\u00d6berg KFalconi FKrenning EPSundin APerren ABerruti A & ESMO Guidelines Committee. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology202031844\u2013860. (https:\/\/doi.org\/10.1016\/j.annonc.2020.03.304)"},{"key":"bib19","series-title":"Histopathology","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","unstructured":"Nagtegaal IDOdze RDKlimstra DParadis VRugge MSchirmacher PWashington KMCarneiro FCree IA & WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology202076182\u2013188. (https:\/\/doi.org\/10.1111\/his.13975)10.1111\/his.13975"},{"key":"bib20","series-title":"Annals of Oncology","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/annonc\/mdv626","article-title":"Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors","volume":"27","author":"van Adrichem","year":"2016","unstructured":"van Adrichem RCSKamp KVandamme TPeeters MFeelders RADe Herder WW. Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. Annals of Oncology201627746\u2013747. (https:\/\/doi.org\/10.1093\/annonc\/mdv626)10.1093\/annonc\/mdv626"},{"key":"bib21","series-title":"Endocrine Connections","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1530\/EC-17-0276","article-title":"Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs","volume":"7","author":"Lv","year":"2018","unstructured":"Lv YHan XZhang CFang YPu NJi YWang DXuefeng XLou W. Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs. Endocrine Connections20187169\u2013178. (https:\/\/doi.org\/10.1530\/EC-17-0276)10.1530\/EC-17-0276"},{"key":"bib22","series-title":"Endokrynologia Polska","doi-asserted-by":"publisher","first-page":"308","DOI":"10.5603\/EP.a2021.0060","article-title":"Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues","volume":"72","author":"Gut","year":"2021","unstructured":"Gut PCzarnywojtek ASawicka-Gutaj NWolinski KMaciejewski AKomarnicki PRucha\u0142a M. Determination of neuron-specific enolase in patients with midgut-type tumour treated with somatostatin analogues. Endokrynologia Polska202172308\u2013318. (https:\/\/doi.org\/10.5603\/EP.a2021.0060)10.5603\/EP.a2021.0060"},{"key":"bib23","series-title":"Frontiers in Oncology","article-title":"Development and validation of novel nomograms using serum tumor markers for the prediction of preoperative histologic grades in gastroenteropancreatic neuroendocrine tumors","volume":"11","author":"Li","year":"2021","unstructured":"Li YWu ZQXu QGoyal HXu HG. Development and validation of novel nomograms using serum tumor markers for the prediction of preoperative histologic grades in gastroenteropancreatic neuroendocrine tumors. Frontiers in Oncology202111 681149. (https:\/\/doi.org\/10.3389\/fonc.2021.681149)"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/11\/9\/EC-21-0647.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/9\/EC-21-0647.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/11\/9\/EC-21-0647.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:45:18Z","timestamp":1784555118000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/1038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":23,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.1530\/ec-21-0647","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}